Through a series of case studies, this slide deck considers the evidence linking key risk factors to elevated Lp(a) (ethnicity, genetics, menopause, kidney diseases, thyroid disease) and, in the absence of specific Lp(a) targeting agents, the guidelines-based risk management recommendations for patients in high Lp(a) risk groups.
In this slide deck, we address some of the key questions about what makes Lp(a) such an important risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis, including the impact of apo(a) isoform size on Lp(a) concentration, and the role of Lp(a) as a major carrier of proinflammatory oxidised phospholipids.
Download slides >>
Download slides >>
Download slides >>
Download slides >>
Download slides >>
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
